CU-NP is a natriuretic peptide designed by researchers at Mayo Clinic that consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type natriuretic peptide, or CNP, and the N- and C-termini of Urodilatin, or URO, which exhibits cardiac unloading actions while minimizing the blood pressure lowering effects of CNP and augmenting the physiological effects of natriuresis.

Preclinical studies of CU-NP have shown it to:

  • Increase the release of sodium by increasing elimination (via urine)
  • Increase glomerular filtration rate (a measure of kidney function) in a dose dependent manner
  • Decrease pressures in the heart
  • Regulate the fluid balance in the body without significantly reducing blood pressure

There is no plan to conduct a clinical trial of CU-NP at this time.


View a list of publications relating to CU-NP.